Geneia Chief Analytics and Technology Officer to discuss AI at Rogosin Institute
October 18, 2019
New York, NY – Geneia, a healthcare analytic solutions and services company that is simplifying the evolution to value-based care, announced Fred Rahmanian, chief analytics and technology officer, is participating in today’s Rogosin Institute expert roundtable, Potential Power and Challenges in the Use of Artificial Intelligence (AI) for Improved Risk Stratification and Management of Kidney Disease. The roundtable will address the current role of AI in helping prevent and treat kidney disease; assess what is needed to make AI platforms more effective and practical for their intended usage, including the incorporation of the social determinants of health (SDoH); and consider what further work can be done for AI to help deliver better, more proactive and more affordable kidney care.
“At the Geneia Data Intelligence Lab, we’re using artificial intelligence and leading-edge data science techniques to create faster, easier, more accurate and prescriptive analytics to address areas of highest cost and disease burden,” said Rahmanian. “I am excited to share our work on diabetes and the ability to predict which type 2 diabetics will experience a diabetes-related complication such as kidney failure. Healthcare organizations can then intervene and direct identified, at-risk patients towards high-value preventive and self-care options.”
There are an estimated 40 million Americans with chronic kidney disease, which, in all of its stages, accounts for 23 percent of Medicare spending and $113 billion dollars annually. Like the Rogosin Institute, an independent, not-for-profit treatment and research center affiliated with New York-Presbyterian Hospital and Weill Cornell Medical College, Geneia believes in the strong potential of AI to improve the care and costs of kidney disease and other chronic illnesses. For more information about the Rogosin Institute, click here.
Geneia LLC is a healthcare analytics and services company. We work to improve collaboration between healthcare providers, health plans and employers to better support personalized, patient-centered care. Through advanced technology, education and training, insights and clinical services, we help clients better identify and actively manage high-risk populations, improve quality measurement and outcomes, and strengthen revenue. Rooted in deep clinical experience and leading-edge data science, our client-centric, phased approach to population health simplifies the transition to risk and value-based care. Our offices are located in Harrisburg, PA and Manchester, NH. To learn more, visit Geneia.com (https://www.geneia.com) or connect with us on Facebook, Twitter and LinkedIn.